在脑梗塞的内血管治疗中进行再输血的glenzocimab:GREEN研究
Mikaël Mazighi1,2, Jerome Lambert3,4, Benjamin Gory5
1Deparment of Neurology, Université Paris Cité, Institut Universitaire de France, GH Lariboisiere Fernand-Widal, Paris, France mmazighi@for.paris.
Journal of neurointerventional surgery
|August 27, 2025
概括
在治疗急性缺血性中风 (AIS) 中,glenzocimab通过抑制血栓生长具有前景. 在GREEN研究中,评估glenzocimab与内血管治疗 (EVT) 结合是否改善患者中风后的功能结果.
科学领域:
- 神经学
- 药理学
- 心血管研究
背景情况:
- 针对血小板糖蛋白VI的单克隆抗体片段glenzocimab在低出血风险下具有抑制血栓形成的潜力.
- 之前的研究表明,在接受内血管治疗 (EVT) 的急性缺血性中风 (AIS) 患者中,glenzocimab可增强再输液并减少出血转化.
研究的目的:
- 在AIS患者中,与安慰剂加EVT相比,评估glenzocimab与EVT一起使用的疗效.
- 为了确定glenzocimab是否改善了接受EVT的AIS患者的功能结果.
主要方法:
- 这是一项多中心,随机,双盲,安慰剂对照的试验.
- 在症状出现后24小时内患有前部大血管封闭症的参与者随机分别接受静脉注射glenzocimab或安慰剂以及标准EVT (有或没有IVT).
- 主要疗效终点是通过修改后的兰金尺度评估的功能结果.
主要成果:
- 这个部分在提供的摘要中没有.
结论:
- 这是第一个随机试验,旨在评估glenzocimab与EVT对AIS的疗效.
- 这项研究旨在确定glenzocimab是否改善了因中风而接受EVT的患者的功能结果.
更多相关视频
相关概念视频
Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome III: Diagnostic Studies
500
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
500
Acute Coronary Syndrome IV: Interprofessional Care
525
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
525


